Companies › Rakuten Medical
2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ASP-1929 Photoimmunotherapy (PIT) Anti-EGFR photoimmunotherapy agent | EGFR | Phase 3 | Head and Neck Cancer; Recurrent Head and Neck Squamous Cell Carcinoma | Jun 2027 |
| Cetuximab Sarotalocan (ASP-1929) Epidermal growth factor receptor erbB1 binding agent | EGFR | Phase 3 | Recurrent Head and Neck Squamous Cell Carcinoma | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03769506 | ASP-1929 Photoimmunotherapy (PIT) | Phase 3 | Head and Neck Cancer | Oncology | Dec 2025 |
| NCT04305795 | ASP-1929 Photoimmunotherapy (PIT) | Phase 1 | Recurrent Head and Neck Squamous Cell Carcinoma | Oncology | Jun 2027 |
| NCT06699212 | Cetuximab Sarotalocan (ASP-1929) | Phase 3 | Recurrent Head and Neck Squamous Cell Carcinoma | Oncology | Sep 2028 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Wayshine Biopharm Jiangsu Alphamab Biopharmaceuticals ArriVent BioPharma Black Diamond Therapeutics Nanjing Sanhome Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.